7 results match your criteria: "Neurology Department University Hospital Marqués de Valdecilla and IDIVAL[Affiliation]"
Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.
JAMA Neurol
March 2022
Neuropsychiatric Epidemiology Unit, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
Article Synopsis
- The study investigates the prevalence of amyloid aggregation, a key feature of Alzheimer's disease, in individuals with varying cognitive statuses, including those with normal cognition and who have clinical AD dementia.
- It analyzes how factors like age, sex, educational background, and the method of detecting amyloid (CSF or PET scans) influence the prevalence estimates.
- Data were collected from 85 study cohorts between 2013 and 2020, using a systematic approach to categorize amyloid measurements as normal or abnormal.
How does the brain change in chronic migraine? Developing disease biomarkers.
Cephalalgia
April 2021
Neurology Department, Mayo Clinic, Scottsdale, AZ, USA.
Background: Validated chronic migraine biomarkers could improve diagnostic, prognostic, and predictive abilities for clinicians and researchers, as well as increase knowledge on migraine pathophysiology.
Objective: The objective of this narrative review is to summarise and interpret the published literature regarding the current state of development of chronic migraine biomarkers.
Findings: Data from functional and structural imaging, neurophysiological, and biochemical studies have been utilised towards the development of chronic migraine biomarkers.
Serum CGRP, VIP, and PACAP usefulness in migraine: a case-control study in chronic migraine patients in real clinical practice.
Mol Biol Rep
September 2020
Neurology Department University Hospital Marqués de Valdecilla and IDIVAL, Avda Valdecilla s/n, 39008, Santander, Cantabria, Spain.
Calcitonin gene-related peptide (CGRP), vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypetide-38 (PACAP-38) have relevant roles in migraine pathophysiology. Their serum levels have been proposed as biomarkers for migraine. Our aim was to assess their diagnostic value in real clinical practice in a cohort of chronic migraine (CM), episodic migraine (EM) and healthy controls (HC).
View Article and Find Full Text PDFVascular safety of erenumab for migraine prevention.
Neurology
February 2020
From California Medical Clinic for Headache (D.K.), Santa Monica, CA; Department of Neurology (J.P.), University Hospital Marqués de Valdecilla and IDIVAL, Santander, Spain; Premiere Research Institute (P.K.W.), Nova Southeastern University, West Palm Beach, FL; Department of Neurology (D.W.D.), Mayo Clinic, Phoenix, AZ; Department of Neurology (S.J.T.), Geisel School of Medicine at Dartmouth, Hanover, NH; Department of Neurology (U.R.), Charité Universitätsmedizin Berlin, Germany; Novartis, East Hanover, NJ (F.H.), and Basel, Switzerland (J.K.); Amgen Inc. (F.Z., S.C., H.P., O.E., J.W., D.D.M.), Thousand Oaks, CA; and PharmaScribe, LLC (J.N.L.), Atlanta, GA.
Objective: To examine the cardiovascular, cerebrovascular, and peripheral vascular safety of erenumab across migraine prevention studies.
Methods: Vascular adverse events (AEs) and blood pressure data were integrated across 4 double-blind, placebo-controlled studies of erenumab and their open-label extensions in patients with chronic or episodic migraine. Subgroup analyses were conducted by acute migraine-specific medication use and number of vascular risk factors at baseline.
Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe.
Cephalalgia
December 2017
9 Pharmacoepidemiology and Risk Management, RTI Health Solutions, Waltham, MA, USA.
Objective To examine treatment utilization patterns and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine in routine clinical practice. Background Clinical trials support onabotulinumtoxinA for the prophylaxis of headache in patients with chronic migraine, but real-world data are limited. Design/methods A prospective, observational, post-authorization study in adult patients with chronic migraine treated with onabotulinumtoxinA.
View Article and Find Full Text PDFAMG 334 CGRP antibody for migraine: time to celebrate?
Lancet Neurol
April 2016
University Hospital Marqués de Valdecilla and IDIVAL, 39008 Santander, Spain. Electronic address:
European Headache Federation consensus on technical investigation for primary headache disorders.
J Headache Pain
September 2016
Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy.
The diagnosis of primary headache disorders is clinical and based on the diagnostic criteria of the International Headache Society (ICHD-3-beta). However several brain conditions may mimic primary headache disorders and laboratory investigation may be needed. This necessity occurs when the treating physician doubts for the primary origin of headache.
View Article and Find Full Text PDF